Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 115

Sort by

Sort Order Select

Journal Articles

Gemtuzumab Ozogamicin Plus Intensive Chemotherapy for Patients with NPM1 -Mutated Acute Myeloid Leukemia

Blood (2022) 140 (Supplement 1): 2010–2013.

https://doi.org/10.1182/blood-2022-166084

Published: 2022

Journal Articles

Midostaurin Plus Intensive Chemotherapy for Younger and Older Patients with Acute Myeloid Leukemia and FLT3 Internal Tandem Duplications

Blood (2021) 138 (Supplement 1): 692.

https://doi.org/10.1182/blood-2021-147256

Published: 2021

Journal Articles

Clonal evolution of acute myeloid leukemia with FLT3 -ITD mutation under treatment with midostaurin

Blood (2021) 137 (22): 3093–3104.

https://doi.org/10.1182/blood.2020007626

Published: 2021

Includes: Supplemental data

Journal Articles

Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1 -mutated AML: results from the AMLSG 09-09 trial

Blood (2020) 136 (26): 3041–3050.

https://doi.org/10.1182/blood.2020005998

Published: 2020

Includes: Supplemental data

Journal Articles

Mutational Landscape of Relapsed Core-Binding Factor Acute Myeloid Leukemia (CBF-AML)

Blood (2020) 136 (Supplement 1): 42.

https://doi.org/10.1182/blood-2020-142392

Published: 2020

Journal Articles

The Combination of AXL Inhibitor Bemcentinib and Low Dose Cytarabine Is Well Tolerated and Efficacious in Elderly Relapsed AML Patients: Update from the Ongoing BGBC003 Phase II Trial (NCT02488408)

Blood (2020) 136 (Supplement 1): 14.

https://doi.org/10.1182/blood-2020-136566

Published: 2020

Journal Articles

Higher Dose of CPX-351 Is Associated with Prolonged Hematologic Recovery: Results from an Interim Safety Analysis of the Randomized, Phase III AMLSG 30-18 Trial

Blood (2020) 136 (Supplement 1): 46–47.

https://doi.org/10.1182/blood-2020-138738

Published: 2020

Journal Articles

Next-Generation Sequencing (NGS)-Based Measurable Residual Disease (MRD) Monitoring in Acute Myeloid Leukemia with FLT3 Internal Tandem Duplication ( FLT3 -ITD + AML) Treated with Additional Midostaurin

Blood (2020) 136 (Supplement 1): 21–22.

https://doi.org/10.1182/blood-2020-137568

Published: 2020

Journal Articles

Ivosidenib Improves Overall Survival Relative to Standard Therapies in Relapsed or Refractory Mutant IDH1 AML: Results from Matched Comparisons to Historical Controls

Blood (2020) 136 (Supplement 1): 18–19.

https://doi.org/10.1182/blood-2020-136957

Published: 2020

Journal Articles

Post Transplantation Measurable Residual Disease (MRD) Monitoring Using Next-Generation Sequencing Is Highly Predictive for Relapseafter Allogeneic Stem Cell Transplantation

Blood (2019) 134 (Supplement_1): 184.

https://doi.org/10.1182/blood-2019-125532

Published: 2019

Journal Articles

Improved Overall Survival with Enasidenib Compared with Standard of Care Among Patients with Relapsed or Refractory Acute Myeloid Leukemia and IDH2 Mutations: A Propensity Score Matching Analysis Using Data from the AG221-C-001 Trial and Two Data Sources from France and Germany

Stephane De Botton, Joseph M Brandwein, MD, Eytan M. Stein, MD, Andrew H. Wei, Daniela Weber, Arnaud Pigneux, Nicolas Boissel, MD PhD, Peter Paschka, MD, Konstanze Döhner, Salem Abi Nehme, Mark G. Frattini, MD, Roland Marion-Gallois, Jixian (Jason) Wang, Chris Cameron, Muhaimen Siddiqui, Rana A. Qadeer, Hartmut Döhner

Blood (2019) 134 (Supplement_1): 3893.

https://doi.org/10.1182/blood-2019-122700

Published: 2019

Journal Articles

Durable Responses Observed in Elderly AML Patients Unfit for Intensive Chemotherapy with First-in Class Selective AXL Inhibitor Bemcentinib (BGB324) in Combination with LDAC: Phase II Open-Label Study

Blood (2019) 134 (Supplement_1): 3943.

https://doi.org/10.1182/blood-2019-128683

Published: 2019

Journal Articles

Measurable Residual Disease (MRD) Monitoring in Acute Myeloid Leukemia (AML) with t(8;21)(q22;q22.1) RUNX1 - RUNX1T1 Identifies Patients at High Risk of Relapse: Results of the AML Study Group (AMLSG)

Blood (2019) 134 (Supplement_1): 2740.

https://doi.org/10.1182/blood-2019-125584

Published: 2019

Journal Articles

AGILE: A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Ivosidenib in Combination with Azacitidine in Adult Patients with Previously Untreated Acute Myeloid Leukemia with an IDH1 Mutation

Pau Montesinos Fernandez, MD PhD, Christian Recher, MD PhD, Vadim Doronin, MD, Rodrigo T. Calado, MD PhD, Jun Ho Jang, MD PhD, Yasushi Miyazaki, MD PhD, Jianxiang Wang, MD, Diego A Gianolio, PhD, Scott R. Daigle, MS, Thomas Winkler, MD, Vickie Zhang, PhD, Peter Paschka, MD

Blood (2019) 134 (Supplement_1): 2593.

https://doi.org/10.1182/blood-2019-123045

Published: 2019

Journal Articles

Low-Dose Azacitidine, Pioglitazone and All-Trans Retinoic Acid Versus Standard-Dose Azacitidine in Patients ≥ 60 Years with Acute Myeloid Leukemia Refractory to Standard Induction Chemotherapy (AMLSG 26-16/AML-ViVA): Results of the Safety Run-in Phase I

Daniel Heudobler, Sebastian Klobuch, MD, Florian Lüke, MD, Joachim Hahn, MD, Matthias Grube, MD, Stephan Kremers, MD, Thomas Südhoff, MD, Jörg Westermann, MD, Marie-Luise Huetter-Kroenke, MD, Peter Paschka, MD, Gauthier Bouche, Hartmut Döhner, MD, Wolfgang Herr, MD, Simone Thomas, MD, Albrecht Reichle, MD

Blood (2019) 134 (Supplement_1): 1382.

https://doi.org/10.1182/blood-2019-129977

Published: 2019

Journal Articles

Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group

Blood (2019) 134 (19): 1608–1618.

https://doi.org/10.1182/blood.2019001425

Published: 2019

Includes: Supplemental data

Journal Articles

NPM1c alters FLT3-D835Y localization and signaling in acute myeloid leukemia

Alina Rudorf, Tony Andreas Müller, Cathrin Klingeberg, Stefanie Kreutmair, Teresa Poggio, Sivahari Prasad Gorantla, Tamina Rückert, Annette Schmitt-Graeff, Anina Gengenbacher, Peter Paschka, Claudia Baldus, Robert Zeiser, George S. Vassiliou, Allan Bradley, Justus Duyster, Anna Lena Illert

Blood (2019) 134 (4): 383–388.

https://doi.org/10.1182/blood.2018883140

Published: 2019

Includes: Supplemental data

Journal Articles

Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3 -ITD

Blood (2019) 133 (8): 840–851.

https://doi.org/10.1182/blood-2018-08-869453

Published: 2019

Includes: Supplemental data

Journal Articles

Final Analysis of the Dose Escalation, Expansion and Biomarker Correlations in the Ph I/II Trial BGBC003 with the Selective Oral AXL Inhibitor Bemcentinib (BGB324) in Relapsed/Refractory AML and MDS

Sonja Loges, MD, PhD, Michael Heuser, MD, Joerg Chromik, Carlos E Vigil, MD, Peter Paschka, MD, Isabel Ben-Batalla, PhD, Nuray Akyüz, David Micklem, Robert Holt, Anthony Brown, James Lorens, Murray Yule, Maxim Kebenko, MD, Melanie Janning, Mascha Binder, MD, Walter Fiedler, MD, Jorge E. Cortes, MD, Bjorn Gjertsen, MD PhD

Blood (2018) 132 (Supplement 1): 2672.

https://doi.org/10.1182/blood-2018-99-120380

Published: 2018

Journal Articles

A Phase 1 First-in-Human Study of AMG 330, an Anti-CD33 Bispecific T-Cell Engager (BiTE ® ) Antibody Construct, in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

Farhad Ravandi, MD, Anthony S. Stein, MD, Hagop M. Kantarjian, MD, Roland B. Walter, MD PhD MS, Peter Paschka, MD, Mojca Jongen-Lavrencic, MD PhD, Gert J. Ossenkoppele, MD PhD, Zhao Yang, Bhakti Mehta, Marion Subklewe, MD

Blood (2018) 132 (Supplement 1): 25.

https://doi.org/10.1182/blood-2018-99-109762

Published: 2018

NARROW

Gemtuzumab Ozogamicin Plus Intensive Chemotherapy for Patients with NPM1 -Mutated Acute Myeloid Leukemia

Midostaurin Plus Intensive Chemotherapy for Younger and Older Patients with Acute Myeloid Leukemia and FLT3 Internal Tandem Duplications

Clonal evolution of acute myeloid leukemia with FLT3 -ITD mutation under treatment with midostaurin

Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1 -mutated AML: results from the AMLSG 09-09 trial

Mutational Landscape of Relapsed Core-Binding Factor Acute Myeloid Leukemia (CBF-AML)

The Combination of AXL Inhibitor Bemcentinib and Low Dose Cytarabine Is Well Tolerated and Efficacious in Elderly Relapsed AML Patients: Update from the Ongoing BGBC003 Phase II Trial (NCT02488408)

Higher Dose of CPX-351 Is Associated with Prolonged Hematologic Recovery: Results from an Interim Safety Analysis of the Randomized, Phase III AMLSG 30-18 Trial

Next-Generation Sequencing (NGS)-Based Measurable Residual Disease (MRD) Monitoring in Acute Myeloid Leukemia with FLT3 Internal Tandem Duplication ( FLT3 -ITD + AML) Treated with Additional Midostaurin

Ivosidenib Improves Overall Survival Relative to Standard Therapies in Relapsed or Refractory Mutant IDH1 AML: Results from Matched Comparisons to Historical Controls

Post Transplantation Measurable Residual Disease (MRD) Monitoring Using Next-Generation Sequencing Is Highly Predictive for Relapseafter Allogeneic Stem Cell Transplantation

Improved Overall Survival with Enasidenib Compared with Standard of Care Among Patients with Relapsed or Refractory Acute Myeloid Leukemia and IDH2 Mutations: A Propensity Score Matching Analysis Using Data from the AG221-C-001 Trial and Two Data Sources from France and Germany

Durable Responses Observed in Elderly AML Patients Unfit for Intensive Chemotherapy with First-in Class Selective AXL Inhibitor Bemcentinib (BGB324) in Combination with LDAC: Phase II Open-Label Study

Measurable Residual Disease (MRD) Monitoring in Acute Myeloid Leukemia (AML) with t(8;21)(q22;q22.1) RUNX1 - RUNX1T1 Identifies Patients at High Risk of Relapse: Results of the AML Study Group (AMLSG)

AGILE: A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Ivosidenib in Combination with Azacitidine in Adult Patients with Previously Untreated Acute Myeloid Leukemia with an IDH1 Mutation

Low-Dose Azacitidine, Pioglitazone and All-Trans Retinoic Acid Versus Standard-Dose Azacitidine in Patients ≥ 60 Years with Acute Myeloid Leukemia Refractory to Standard Induction Chemotherapy (AMLSG 26-16/AML-ViVA): Results of the Safety Run-in Phase I

Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group

NPM1c alters FLT3-D835Y localization and signaling in acute myeloid leukemia

Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3 -ITD

Final Analysis of the Dose Escalation, Expansion and Biomarker Correlations in the Ph I/II Trial BGBC003 with the Selective Oral AXL Inhibitor Bemcentinib (BGB324) in Relapsed/Refractory AML and MDS

A Phase 1 First-in-Human Study of AMG 330, an Anti-CD33 Bispecific T-Cell Engager (BiTE ® ) Antibody Construct, in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only